C

Cooper Companies

Global medical devices and vision care

Process Flow Leader

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Bachelor's
Juana Díaz, Puerto Rico
In Person
Warehouse & Fulfillment

About the job

Requirements
  • More than three years of experience in a similar position and/or experience working in a warehouse.
  • A bachelor's degree or more than three years of experience in a similar position.
  • Basic knowledge of Microsoft Office Excel, Word, PowerPoint, BPCS, and AGILE.
  • Basic concepts in problem solving, workload balancing, and root cause analysis.
  • Knowledge of inventory controls.
  • Ability to make sound decisions and exercise judgment and information analysis.
  • Knowledge of effective meetings and basic conflict management.
  • Written and oral communication skills.
  • Ability to work with minimal supervision.
  • Ability to walk, stand, use hands to handle objects, sit, reach, lift or move up to 50 pounds, and work with close vision; the role involves light physical effort and some exposure to cold, wet or humid conditions and moving mechanical parts.
Responsibilities
  • Coordinate daily warehouse process flow, assign task priorities, verify and manage inventory controls for raw materials, product supplies, and silver stock, and ensure product flow supports Manufacturing and Packaging Operations' daily needs.
  • Monitor warehouse efficiency, including space utilization and inventory accuracy.
  • Maintain a healthy work environment by complying with procedures, company policies, operational standards, and safety standards.
  • Maintain raw materials and silver stock inventory accuracy and generate nonconforming product and material reports.
  • Ensure warehouse personnel perform their duties with quality awareness; identify disciplinary situations, provide associate feedback, and elevate situations to the area manager or leader for investigation.
  • Ensure warehouse resources are available and compliant, including certified personnel, operational equipment, equipment calibration and preventive maintenance, and operational supplies.
  • Coordinate associates' vacation plans and ensure warehouse goals are achieved.
  • Monitor daily warehouse activities, including picking, shipping, put-away, and dispatch, and monitor shift and unit performance and indicators.
  • Perform daily safety monitoring audits, generate accident and incident reports as needed, ensure repair resources are assigned, and support repairs within the shift.
  • Maintain warehouse information flow and coordinate and conduct regular communications and special warehouse meetings.
  • Support inventory reconciliation activities and promote a positive work environment.
  • Balance workload among area personnel using line-balancing concepts and maintain the ROLES Program within the job area.
  • Perform and document scheduled audits, promote the 6S methodology, suggest improvements, report audit findings, create actions, and complete them.
  • Assist with quality and process issue investigations by gathering data; identify and implement corrective and preventive actions.
  • Assist in identifying resource availability and human-resource requirements by role for warehouse operations.
  • Execute warehouse operations according to applicable standard operating procedures; manage safety and emergency issues and implement safety corrective actions.
  • Measure and improve safety shift indicators and identify process equipment that is not performing as expected.
  • Communicate process capabilities and goals for warehouse operations and ensure the appropriate resources address equipment repairs.
  • Identify corrective and preventive actions, create safe conditions by design, provide ongoing safety education to shift members, and ensure shift accident investigations are complete.
  • Define and prioritize process key performance indicators for improvement, select indicators, map processes to be improved, and improve indicator performance.
  • Develop and deploy improvement plans, coordinate and execute them including validation, create lasting solutions using technology and methodology, and identify opportunities to improve equipment performance.
  • Monitor unit performance and performance indicators; provide people performance appraisals and feedback; coordinate overtime for non-exempt employees.

About the company

Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.

Company Size

201-500

Company Stage

IPO

Headquarters

San Ramon, California

Founded

1958

Get referred to Cooper Companies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 23, 2026 Vision Centre launch accelerates six contact-lens products over several years.
  • Q3 fiscal 2026 free cash flow hit $273 million, up 66% year over year.
  • MiSight grew 20% organically, while MyDay posted double-digit growth in Q3 2026.

What critics are saying

  • Q3 2026 revenue missed by $30 million, and CooperVision destocking continues into Q4.
  • Accrued litigation liability jumped to $316.5 million on July 31, 2026.
  • Kirby McInerney opened a securities investigation after the September 9, 2026 earnings drop.

What makes Cooper Companies unique

  • CooperVision's Southampton Vision Centre unites R&D, pilot manufacturing, clinics, and commercialization.
  • CooperVision reaches 40 million people worldwide through contact lenses and myopia-control leadership.
  • CooperSurgical combines fertility, genomics, and women's-health devices under one vertically integrated platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Paid Vacation
  • Performance Bonus
  • Health Insurance
  • 401(k) Retirement Plan
  • Life Insurance
  • Wellness Program
  • Professional Development Budget

Company News

Yahoo Finance
Oct 27th, 2026
CooperCompanies names Walt Rosebrough executive chair as CEO Al White exits

CooperCompanies named independent director Walt Rosebrough executive chair and said chief executive officer Albert White III is stepping down, effective immediately. Rosebrough will oversee daily operations until a permanent chief executive is appointed. White will stay on as a strategic advisor through April 1, 2027. The medical device maker has hired search firm Russell Reynolds. Rosebrough said recent performance "has not met our expectations." Former Johnson & Johnson executive Shlomi Nachman will join the board as an independent director on December 8, 2026. Directors Barbara Carbone, Colleen Jay, and Robert Weiss will not stand for reelection at the 2027 annual meeting, leaving a seven-member board. The company reaffirmed its fiscal 2026 guidance.

Yahoo Finance
Sep 24th, 2026
CooperVision opens global innovation hub in Southampton, unveils six new contact lens products

The Cooper Companies has opened The Vision Centre, a global innovation hub in Southampton, England, to accelerate contact lens development for its CooperVision business. The facility integrates research and development, clinical expertise, pilot manufacturing and commercial capabilities under one roof. CooperVision announced six product advancements across myopia control, silicone hydrogel, toric and multifocal contact lenses, with launches planned over coming years. The pipeline includes a complete family of one-day contact lenses for myopia control and a premium one-day silicone hydrogel technology. Following the announcement, COO stock gained 1.4%. Year to date, shares have declined 31.6% against the industry's 2.8% growth. The company has a market capitalisation of $10.51 billion. CooperVision's products currently reach more than 40 million people worldwide.

Associated Press
Sep 24th, 2026
Cooper Companies shares drop 14.7% after missing Q3 revenue target by $30M

Cooper Companies' shares fell 14.7% on 10 September 2026 after the medical device company reported third-quarter revenue of $1.07 billion, missing analyst expectations of $1.10 billion by $30 million. The company attributed the shortfall to its CooperVision segment, which generated $717 million in quarterly revenue, flat year-over-year. Cooper Companies said it had "proactively reduced U.S. channel inventory" in CooperVision, which would continue to impact fourth-quarter results. The share price dropped from $63.48 to close at $54.17 following the announcement. Law firm Kirby McInerney has announced an investigation into possible securities law violations by the company and its senior management. No lawsuit has been filed yet.

PR Newswire
Sep 14th, 2026
The Cooper Companies (NASDAQ: COO) scrutinized over U.S. Channel inventory reductions driving stock sharply lower - HBSS.

The Cooper Companies (NASDAQ: COO) scrutinized over U.S. Channel inventory reductions driving stock sharply lower - HBSS. Sep 14, 2026, 12:46 ET SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ - investors in The Cooper Companies, Inc. (NASDAQ: COO) saw the price of their shares trade down $9.31 (-14.6%) after the company reported Q3 2026 financial results that included revelations of its U.S. channel inventory destocking along with other negative surprises. The stock's move lower wiped out over $1.7 billion of the company's market capitalization. The revelations have prompted national shareholders rights firm Hagens Berman to open an investigation into whether The Cooper Companies was sufficiently transparent beforehand about its sales practices and, if not, whether it may have violated the securities laws. The firm encourages Cooper investors who suffered substantial losses to submit your losses now. Persons with knowledge who may be able to assist the investigation are invited to contact the firm's attorneys. The Cooper Companies (COO) Investigation Cooper is a global medical device company with two reporting segments. The largest - CooperVision - manufactures and markets hydrogel lens products for contact lens wearers and accounted for roughly 67% of Cooper's total consolidated sales in fiscal 2025. The investigation is focused on the propriety of Cooper's statements about the mechanics contributing to CooperVision's revenue growth and its sustainability. During Cooper's June 4, 2026 Q2 2026 earnings call, management emphasized CooperVision's "solid quarter, with revenues increasing 8%, or 4% organically" and guided for CooperVision full year organic revenue growth of 3.5% to 4.5%, emphasizing that "[f]or CooperVision [...] [o]utside of Asia Pac, demand remains solid for premium products, including daily silicone hydrogel lenses as well as torics and multifocals." The next day, the price of Cooper shares traded almost 8% higher. Investors received some troubling news on September 9, 2026, when the company reported its Q3 2026 financial results. In particular, Cooper's management revealed "our legacy hydrogels were down double-digit across the board[,]" "the results in the Americas reflected CooperVision's US channel inventory reductions[,]" and "[w]e expect CooperVision revenue of $692 million to $706 million down 2% to flat organically." In response to an analyst's question during the earnings call about whether the entirety of the reduced guide for CooperVision revenue was inventory-related, CEO Albert White III said, "it's all destock [...] [m]eaning the entire reason for the reduction in the revenue guidance for CooperVision was tied to just channel inventory." Another analyst expressed concern, asking "why are they destocking [...] [d]id you guys have too much inventory in the channel from past efforts to kind of prop up numbers?" The market did not take kindly to the developments and sent the price of Coopers shares down over 14% the next day to close at a 52-week low of $54.17, with several analysts reportedly downgrading their ratings and price targets. "We're focused on whether Cooper was sufficiently transparent to investors about its CooperVision sales strategies," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation. If you invested in Cooper and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now" Whistleblowers: Persons with non-public information regarding Cooper should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. Attorney Advertising. Prior results do not guarantee a similar outcome in any future case. SOURCE Hagens Berman Sobol Shapiro LLP

Yahoo Finance
Sep 14th, 2026
Cooper Companies cuts 2026 forecast as contact lens demand weakens, CooperVision revenue drops to $717M

The Cooper Companies cut its fiscal 2026 profit and revenue forecasts after weaker-than-expected contact lens demand affected its CooperVision business. The company now expects adjusted earnings of $4.51–$4.55 per share, down from $4.58–$4.66, whilst revenue guidance was reduced to $4.23–$4.25 billion from $4.29–$4.32 billion. Third-quarter revenue came in at $1.07 billion, below Wall Street's $1.10 billion estimate. CooperVision revenue fell to $717 million, with management citing US channel inventory reductions that are expected to continue affecting the fourth quarter. The company completed its strategic review and decided to retain CooperSurgical rather than sell the business. Despite the challenges, Cooper increased its share-repurchase authorisation from $2 billion to $3 billion.